Compare · BTAI vs TNYA
BTAI vs TNYA
Side-by-side comparison of BioXcel Therapeutics Inc. (BTAI) and Tenaya Therapeutics Inc. (TNYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BTAI focuses on Biotechnology: Pharmaceutical Preparations, while TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- TNYA is the larger of the two at $93.1M, about 40.2x BTAI ($2.3M).
- Over the past year, BTAI is down 96.8% and TNYA is down 79.6% - TNYA leads by 17.2 points.
- TNYA has hit the wire 1 time in the past 4 weeks while BTAI has been quiet.
- BTAI has more recent analyst coverage (12 ratings vs 7 for TNYA).
- Company
- BioXcel Therapeutics Inc.
- Tenaya Therapeutics Inc.
- Price
- $0.07-34.28%
- $0.37-8.99%
- Market cap
- $2.3M
- $93.1M
- 1M return
- -91.06%
- -44.40%
- 1Y return
- -96.79%
- -79.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 0
- 1
- Recent ratings
- 12
- 7
BioXcel Therapeutics Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest BTAI
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership
- BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 4 filed by Director Atkins Susan E.
- SEC Form 3 filed by new insider Atkins Susan E.
- Amendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.
- SEC Form 10-Q filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Latest TNYA
- SEC Form PRE 14A filed by Tenaya Therapeutics Inc.
- Chief Executive Officer Ali Faraz was granted 122,000 shares, increasing direct ownership by 29% to 539,782 units (SEC Form 4)
- Chief Medical Officer Tingley Whittemore was granted 49,000 shares, increasing direct ownership by 23% to 263,073 units (SEC Form 4)
- Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
- SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.
- Chief Executive Officer Ali Faraz sold $15,778 worth of shares (22,232 units at $0.71), decreasing direct ownership by 5% to 417,782 units (SEC Form 4) to cover taxes
- Chief Medical Officer Tingley Whittemore sold $5,270 worth of shares (7,424 units at $0.71), decreasing direct ownership by 3% to 214,073 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Tenaya Therapeutics Inc.
- SEC Form S-8 filed by Tenaya Therapeutics Inc.
- SEC Form 10-Q filed by Tenaya Therapeutics Inc.